Literature DB >> 17914562

Microsatellite instability and clinicopathological features in esophageal squamous cell cancer.

Yusuke Matsumoto1, Takeshi Nagasaka, Takeshi Kambara, Naoko Hoshizima, Jun Murakami, Hiromi Sasamoto, Masao Hosokawa, Yoshio Naomoto, Hiroshi Isozaki, Kenji Shimizu, Noriaki Tanaka, Nagahide Matsubara.   

Abstract

Since multiple genetic alterations are involved in the molecular pathogenesis of esophageal squamous cell cancer (ESCC), the role of microsatellite instability (MSI) in its carcinogenesis is not well defined. The reported frequency of MSI in ESCC ranges from 2 to 66.7% but the majority of the results are derived from relatively small studies. Therefore, we carried out a precise MSI analysis on a large number of ESCC samples to clarify the significance of MSI in the ESCC tumorigenesis. The MSI status of the DNA extracted from 62 ESCC samples and 62 counterpart-normal esophageal epitheliums were studied with five NCI panel markers and ten microsatellite markers located in 17q24-25. Forty-four paraffin-embedded samples and 18 frozen samples from the ESCC patients who underwent surgery were studied. The MSI status was classified as MSS (microsatellite stable), MSI-L (low-level MSI; <30% of markers examined showed instability) and MSI-H (high-level MSI; >30% of markers reported instability). Among the 62 ESCC cases analyzed by the 15 microsatellite markers, 38 out of 62 cases (61.3%) showed MSS, 19 out of 62 cases (30.6%) showed MSI-L and 5 out of 62 cases (8.1%) showed MSI-H. Although the MSI status was not associated with the status of lymph node metastasis or a histological type of cancer, the depth of cancer invasion was significantly associated with the frequency of MSS status and the levels of MSI-L were inversely correlated with the depth of invasion (T1/T2 vs. T3/4; P=0.0007). However, MSI status was not associated with the prognosis of the ESCC patients. This is the first large scale MSI analysis of the ESCC in comparison with the clinicopathological features. Relatively high frequency of MSI-L was observed in ESCC and the frequency of MSI-L was inversely correlated with the depth of invasion.

Entities:  

Mesh:

Year:  2007        PMID: 17914562

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

Review 1.  Review of the alterations in DNA methylation in esophageal squamous cell carcinoma.

Authors:  Yoshifumi Baba; Masayuki Watanabe; Hideo Baba
Journal:  Surg Today       Date:  2013-01-05       Impact factor: 2.549

2.  Immune checkpoint blockade therapy for esophageal squamous cell carcinoma.

Authors:  Kazuto Harada; Dilsa Mizrak Kaya; Hideo Baba; Jaffer A Ajani
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 3.005

3.  Loss of heterozygosity and microsatellite instability as predictive markers among Iranian esophageal cancer patients.

Authors:  Mohammad Mahdi Forghanifard; Elham Emami Vahid; Ezzat Dadkhah; Mehran Gholamin; Samaneh Broumand Noghabi; Martha Ghahraman; Mehdi Farzadnia; Mohammad Reza Abbaszadegan
Journal:  Iran J Basic Med Sci       Date:  2016-07       Impact factor: 2.699

Review 4.  Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications.

Authors:  Pinhao Fang; Jianfeng Zhou; Zhiwen Liang; Yushang Yang; Siyuan Luan; Xin Xiao; Xiaokun Li; Hanlu Zhang; Qixin Shang; Xiaoxi Zeng; Yong Yuan
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

Review 5.  Aberrant epigenetic patterns in the etiology of gastrointestinal cancers.

Authors:  Paweł Karpiński; Maria M Sasiadek; Nikolaus Blin
Journal:  J Appl Genet       Date:  2008       Impact factor: 2.653

Review 6.  A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.

Authors:  J M Findlay; M R Middleton; I Tomlinson
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

7.  Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study.

Authors:  L C Hewitt; I Z Inam; Y Saito; T Yoshikawa; A Quaas; A Hoelscher; E Bollschweiler; G E Fazzi; V Melotte; R E Langley; M Nankivell; D Cunningham; W Allum; G G Hutchins; H I Grabsch
Journal:  Eur J Cancer       Date:  2018-03-20       Impact factor: 9.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.